TODD BATES: Open Payments
NPI 1063008829 · IDAHO FALLS, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$850 in 18 payments from 10 companies in 2025. Trend: 2023 $1,000 · 2024 $697 · 2025 $850
Food & beverage: $850
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $278 |
| Edwards Lifesciences Corporation | 2 | $126 |
| E.R. Squibb & Sons, L.L.C. | 1 | $125 |
| Vanda Pharmaceuticals Inc. | 5 | $110 |
| Alkermes, Inc. | 1 | $95 |
| Janssen Pharmaceuticals, Inc | 2 | $36 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $24 |
| Neurocrine BioSciences, Inc. | 1 | $23 |
| Janssen Biotech, Inc. | 1 | $17 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
Products named: CAPLYTA, COBENFY, FANAPT, LYBALVI, SAPIEN 3 Ultra RESILIA, INGREZZA, INVEGA SUSTENNA, RYBREVANT.
Industry payments across ID — which companies pay providers there.
